A Post-Marketing Surveillance, Multicenter, Open-Label, Dose-Titrating, 4-Week Study Evaluating The Efficacy, Tolerability And Safety Of Olmesartan Medoxomil 20 Mg In Combination With 12.5 Mg Of Hydrochlorothiazide In Subjects With Mild To Moderate Essential Hypertension.

Trial Profile

A Post-Marketing Surveillance, Multicenter, Open-Label, Dose-Titrating, 4-Week Study Evaluating The Efficacy, Tolerability And Safety Of Olmesartan Medoxomil 20 Mg In Combination With 12.5 Mg Of Hydrochlorothiazide In Subjects With Mild To Moderate Essential Hypertension.

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Dec 2009

At a glance

  • Drugs Hydrochlorothiazide; Olmesartan medoxomil
  • Indications Essential hypertension
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 15 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Jul 2009 Actual patient number (1723) added as reported by ClinicalTrials.gov.
    • 15 Jul 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top